|
Video: What is a Stock Split?
|
|
Cytocom is a biopharmaceutical company. Co.'s product candidate, Entolimod is a Toll-like receptor 5 (TLR5) agonist, which Co. is developing as a medical radiation countermeasure for reducing the risk of death following exposure to potentially lethal irradiation Acute Radiation Syndrome. Co.'s other product candidate, Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, a secretory non-glycosylated version of entolimod Co. is also developing through its subsidiary, Panacela Labs, Inc. Two randomized, placebo-controlled, dose-ranging studies of Mobilan in men with prostate cancer are ongoing in the Russian Federation. According to our CBLI split history records, CBLI has had 1 split. | |
|
CBLI (CBLI) has 1 split in our CBLI split history database. The split for CBLI took place on January 28, 2015. This was a 1 for 20 reverse split, meaning for each 20 shares of CBLI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as CBLI conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CBLI split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CBLI shares, starting with a $10,000 purchase of CBLI, presented on a split-history-adjusted basis factoring in the complete CBLI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
08/31/2021 |
|
Start price/share: |
$13.00 |
|
End price/share: |
$3.17 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-75.62% |
|
Average Annual Total Return: |
-17.44% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,438.15 |
|
Years: |
7.36 |
|
|
|
Date |
Ratio |
01/28/2015 | 1 for 20 |
|
|